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Abstract
Neuropathic pain is caused by lesion or dysfunction of the peripheral sensory nervous system. Up-regulation
of the voltage-gated Ca2+ channel subunit α2δ-1 in DRG (dorsal root ganglion) neurons and the spinal cord
correlates with the onset of neuropathic pain symptoms such as allodynia in several animal models of
neuropathic pain. The clinically important anti-allodynic drugs gabapentin and pregabalin are α2δ-1 ligands,
but how these drugs alleviate neuropathic pain is poorly understood. In the present paper, we review recent
advances in our understanding of their molecular mechanisms.
Neuropathic pain
Unlike nociceptive or acute pain, neuropathic pain occurs
without continuous noxious peripheral input. Patients
with neuropathic pain experience spontaneous pain that
is described as ‘electric-shock-like, burning and tingling’.
Further symptoms of neuropathy are the painful response
to normally innocuous stimuli (allodynia) and the increased
response to noxious stimuli (hyperalgesia). In addition,
patients also suffer from depression, anxiety and insomnia
as a result of their chronic pain condition. A recent survey
showed that up to 8 % of the population of the U.K.
may endure chronic pain of predominantly neuropathic
origin [1].
Neuropathic pain is caused by damage to primary sensory
afferent neurons of the peripheral nervous system that relay
nociceptive and non-nociceptive peripheral stimuli to the
spinal cord and the brain [2] as a result of, e.g., trauma,
diabetes, cancer and chemotherapy [3]. Diabetes is the most
common cause of neuropathic pain in the U.K. The estimated
annual NHS (National Health Service) expenditure on the
treatment of peripheral diabetic neuropathy and its associated
complications is in the range of £250 million and is expected
to rise [4].
The axons of primary sensory afferents form the spinal
nerves and dorsal roots, with their cell bodies residing within
the DRGs (dorsal root ganglia) [2]. Damaged DRG neurons
become hyperexcitable (increased probability to fire action
potentials) and show ectopic activity (spontaneous firing of
action potentials). Hyperexcitability and ectopic activity lead
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to increased transmitter release in the spinal cord and this
causes central sensitization (increased excitability of neurons
within the central nervous system). These changes in neuronal
activity together with increased activation of descending
pathways from the brain are the mechanistic components
in the development and maintenance of neuropathic
pain [3].
The role of the voltage-gated Ca2+
channel subunit α2δ-1 in neuropathic
pain
Voltage-gated Ca2+ channels are heteromultimeric complexes
consisting of the pore-forming Cavα1 subunit that determines
the main biophysical properties of the channel and the
auxiliary subunits β and α2δ (for a review, see [5]).
α2δ increases Ca2+ currents by increasing the number
of functional channels at the plasma membrane through
enhancement of Cavα1 trafficking to the plasma membrane,
and by stabilization of the channels at the cell surface [5].
The α2δ subunit consists of two proteins that are derived
from a single gene product by proteolytic cleavage, namely
the extracellular α2- and the δ-protein that is thought to
be transmembrane. The proteins α2 and δ remain linked via
disulfide bonds. The α2-protein is heavily glycosylated and
harbours the vWF-A (von Willebrand factor-A) domain [5].
An intact vWF-A domain is a prerequisite for the positive
effect of α2δ on Ca2+ channel forward trafficking [6]. So far,
four genes encoding α2δ subunits (α2δ-1–α2δ-4) have been
identified. α2δ-1 was cloned from skeletal muscle, but was
found to be relatively ubiquitously expressed, whereas α2δ-2
and α2δ-3 are more restricted to the brain and α2δ-4 to certain
endocrine tissues and retina [5].
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Figure 1 Distribution of α2δ-1 following SNL
(A) Immunofluorescence images showing the distribution of α2δ-1 in (from left to right) ligated spinal nerve, DRG, dorsal
root and the superficial layers of the spinal cord dorsal horn on the ipsilateral side of the lumbar region L5 compared with
the spinal cord dorsal horn (Lt, Lissauer’s tract; I, II and III, lamina 1, 2 and 3 respectively), the dorsal root and DRG on the
contralateral side. α2δ-1 is up-regulated in the ipsilateral DRG, dorsal root and spinal cord dorsal horn compared with
the contralateral side. Moreover, α2δ-1 accumulates at the ligation site. (B) Illustration of α2δ-1 immunofluorescence staining
and the effect of the chronic pregabalin (PGB) application on the distribution. α2δ-1 protein is up-regulated following spinal
nerve ligation (green arrows). This up-regulation is affected by chronic PGB (red arrow). The size of the red arrow relative
to the green represents the effect of chronic PGB on α2δ-1 distribution. The effect of chronic PGB on the α2δ-1 level in the
fasciculus gracilis was small, but significant [11]. However, there was no detectable effect in the DRGs. The ligation site is
indicated by X.
Accumulating evidence from numerous groups points
to an important role of α2δ in neuropathic pain. α2δ-1
mRNA and protein levels are dramatically up-regulated in
affected DRGs in several models of neuropathic pain, and
this increase in α2δ-1 correlates with the onset of allodynia
[7–11]. In contrast with α2δ-1, α2δ-2 and α2δ-3 were found
to be down-regulated in the unilateral lumbar SNL (spinal
nerve ligation) model of neuropathic pain [12], demonstrating
the dominant role played by α2δ-1 in neuropathy [11].
Furthermore, transgenic mice overexpressing α2δ-1 show
allodynic symptoms even in the absence of nerve damage,
indicating that increased levels of α2δ-1 are sufficient to cause
neuropathic pain [13].
In a recent study [11], we performed a detailed analysis of
the distribution of α2δ-1 in DRG neurons in the SNL model
(Figure 1). DRG neurons are heterogeneous in morphology
and their function correlates with the size of their somata.
Small and medium-sized somata belong to mainly C- and Aδ-
nociceptors, whereas non-nociceptive Aβ fibres have a large
soma [7]. This study showed that α2δ-1 protein levels were
elevated in all three size groups of DRG neuron somata at the
level of ligation, regardless of their function (Figure 1A) [11].
The augmentation occurred in the endoplasmic reticulum and
at the plasma membrane.
α2δ-1 protein levels were also found to be increased in the
dorsal roots that are formed by the central axon branches
of DRG neurons (Figure 1A) [11]. This increase intensified
over days following ligation (experimental time points were
2, 4 and 7 days post-SNL). Within the dorsal roots, α2δ-1 was
localized to tubular-vesicular structures that are implicated in
protein trafficking [11]. A subset of DRG neurons involved
in touch and proprioception do not form synapses with
spinal cord dorsal horn neurons, but their central axons
directly project up to the brainstem. These axons form the
fasciculus gracilis as part of the spinal cord dorsal column, and
transection of the dorsal column prevents tactile allodynia
symptoms in SNL rats [14]. α2δ-1 was increased in the
fasciculus gracilis starting at the level of ligation, and this
augmentation continued up to the brain stem [11].
The majority of DRG neurons, however, form glutama-
tergic synapses on to second-order sensory neurons in the
spinal cord dorsal horn. α2δ-1 levels are increased in the spinal
cord dorsal horn [10,11] and this up-regulation of α2δ-1 is
crucial for the aetiology of neuropathic pain [15]. The increase
occurred in the superficial and to some extents also in the
deeper layers of the dorsal horn (Figure 1A) [11]. This in-
crease in α2δ-1 protein levels was not accompanied by an
increase in α2δ-1 mRNA in the spinal cord dorsal horn
neurons [11], but was due to an increase in α2δ-1 in the
presynaptic terminals of the DRG neurons [11]. Such an
increase in α2δ-1 in presynaptic terminals of affected DRG
neurons is thought to enhance Ca2+ influx at the nerve
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terminals and therefore increases synaptic transmitter release
into the spinal cord which then causes central sensitization
[16].
The α2δ ligands and anti-allodynic drugs
pregabalin and gabapentin inhibit
anterograde trafficking of α2δ
The current first-line treatment of neuropathic pain com-
prises the anticonvulsant gabapentinoid drugs gabapentin
and pregabalin. These drugs have an analgesic effect on
neuropathic neuronal activity without affecting baseline
nociception [17]. Gabapentin was originally designed as an
analogue of GABA (γ -aminobutyric acid) with increased
membrane permeability, but, like its more potent derivative
pregabalin, showed little affinity for the relevant GABA-
binding sites (for a review, see [18]). Various molecular targets
have been proposed (for a review, see [19]), but, to date, just
one high-affinity binding site has been found, namely α2δ
[18].
Of the four known isoforms of α2δ, only α2δ-1 and α2δ-2
interact with the gabapentinoid drugs, and α2δ-1 has a higher
affinity than does α2δ-2 [5]. The arginine residue of α2δ-1
at position 217 close to the vWF-A domain is critical for the
binding [5]. Mutating this arginine residue to alanine (R217A)
greatly reduces drug-binding affinity and R217A knockin
mice develop neuropathic pain that is insensitive to pregabalin
and gabapentin [20]. These observations indicate that the
binding of the gabapentinoid drugs to α2δ-1 is required for
their analgesic effect.
Several studies have shown that pregabalin and gabapentin
reduce neurotransmitter release [18], but the molecular
mechanism of this inhibition is unclear. Transmitter release
by means of stimulus-coupled Ca2+-dependent exocytosis
depends on a tight spatial and temporal interplay of a plethora
of processes and proteins [21]. Transmitters are stored
in specialized vesicles and released in a highly controlled
manner. Fusion of the vesicle with the plasma membrane is the
final step of secretion when Ca2+ that enters the cell through
Ca2+ channels triggers the fusion of the vesicle with the cell
membrane. Therefore an obvious mechanism would be that
the gabapentinoid drugs inhibit Ca2+ channels directly by
binding to α2δ-1, which would then reduce presynaptic Ca2+
influx and subsequent transmitter release. However, evidence
for a direct inhibitory effect of gabapentinoid drugs on native
Ca2+ currents and synaptic transmission is inconclusive
[5]. Whereas some studies reported a small reduction of
Ca2+ current when the drugs were applied acutely, others
did not observe such an acute inhibitory effect on either
heterologously expressed channels or endogenous Ca2+
currents in DRG neurons in vitro [22,23]. Only a prolonged
and chronic application of pregabalin and gabapentin was
able to reduce Ca2+ influx [22,23]. Thus it seems unlikely that
gabapentinoid drugs inhibit Ca2+ channels directly. However,
chronic application of gabapentin and pregabalin reduced
the amount of the Ca2+ channel subunits α2δ and Cavα1 at
the cell surface without affecting their rate of endocytosis
[11,22]. This led to the conclusion that chronic application of
gabapentinoid drugs in vitro reduced Ca2+ influx owing to
a reduction of the forward trafficking of α2δ and Cavα1
to the plasma membrane. Interestingly, to reduce Ca2+
channels at the plasma membrane, gabapentin had to be taken
up into the cell via the system L amino acid transporter and
possibly displaced an endogenous ligand that is a positive
modulator of α2δ forward trafficking [22].
A classical approach to study neuronal protein trafficking
in vivo is to perturb trafficking by nerve ligation or nerve
section. Proteins that are being trafficked accumulate at
the site of the obstruction, and the level of accumulation
is a measure of trafficking activity. In the SNL model of
neuropathic pain, α2δ-1 was found to accumulate proximal to
the SNL site [11]. These results showed for the first time that
endogenous α2δ-1 is indeed subject to anterograde trafficking
from the DRG somata to both peripheral and central
terminals (Figure 1A). Chronic treatment of SNL animals
with repetitive injections of pregabalin had a profound
anti-allodynic effect on neuropathic pain symptoms and it
inhibited the accumulation of α2δ-1 at the SNL site [11].
Moreover, it also reduced α2δ-1 in ascending DRG axons
of the fasciculus gracilis and, most importantly, reduced
the increase of α2δ-1 in the presynaptic terminals of DRG
neurons in the spinal cord dorsal horn. Because chronic
pregabalin and gabapentin had no effect on the up-regulation
of α2δ-1 in DRG somata (Figure 1B) [11,24], these results
strongly suggest that the anti-allodynic effect of chronic
gabapentinoid drug treatment was due to an inhibition of
anterograde trafficking of α2δ-1 in vivo.
Conclusion and outlook
Recent advances in our understanding of the molecular
mechanisms of gabapentinoid drugs indicate that pregabalin
alleviates neuropathic pain by impairing the trafficking of
α2δ-1 to presynaptic terminals of DRG neurons which
would reduce Ca2+ influx and transmitter release in the
spinal cord and subsequently reduce spinal sensitization. This
intracellular effectiveness of pregabalin is a novel molecular
mechanism to explain the anti-allodynic effect of pregabalin
and is in clear contrast with other analgesic drugs that
influence their targets at the cell surface. Further studies are
needed to unravel how and where in the cell gabapentinoid
drugs affect the trafficking machinery of α2δ-1.
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